{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:45:30Z","timestamp":1784241930088,"version":"3.55.0"},"reference-count":58,"publisher":"Baishideng Publishing Group Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2015]]},"DOI":"10.3748\/wjg.v21.i1.233","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T00:48:26Z","timestamp":1420678106000},"page":"233","source":"Crossref","is-referenced-by-count":44,"title":["Interferon therapy in hepatitis C leading to chronic type 1 diabetes"],"prefix":"10.3748","volume":"21","author":[{"given":"Taiba","family":"Zornitzki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36810"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1517\/14740330802423291"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.","DOI":"10.1016\/S0168-8278(96)80184-X"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133:592-599.","DOI":"10.7326\/0003-4819-133-8-200010170-00009"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4065\/75.4.355"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i14.1642"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.2951096"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047904"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08728.x"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, Chiaramonte M. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992;340:548.","DOI":"10.1016\/0140-6736(92)91744-S"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Nakamura K, Kawasaki E, Imagawa A, Awata T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K, Makino H. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care 2011;34:2084-2089.","DOI":"10.2337\/dc10-2274"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01610.x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Eibl N, Gschwantler M, Ferenci P, Eibl MM, Weiss W, Schernthaner G. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha. Eur J Gastroenterol Hepatol 2001;13:295-298.","DOI":"10.1097\/00042737-200103000-00015"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006;18:689-692.","DOI":"10.1097\/00042737-200606000-00018"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci 2002;47:1649-1654.","DOI":"10.1023\/A:1015852110353"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03571.x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-007-0259-1"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007;13:1292-1294.","DOI":"10.3748\/wjg.v13.i8.1292"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease? Diabet Med 2001;18:329-332.","DOI":"10.1046\/j.1464-5491.2001.00492.x"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Recasens M, Aguilera E, Ampurdanés S, Sánchez Tapias JM, Simó O, Casamitjana R, Conget I. Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C. Diabet Med 2001;18:764-767.","DOI":"10.1046\/j.1464-5491.2001.00562.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2010.05.006"},{"key":"ref22","unstructured":"Popescu C, Popescu GA, Arama V. Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis. J Gastrointestin Liver Dis 2013;22:101-104."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-200514"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4137\/CMED.S7815"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.11.016"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Yamazaki M, Sato A, Takeda T, Komatsu M. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Intern Med 2010;49:403-407.","DOI":"10.2169\/internalmedicine.49.2656"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Shiba T, Morino Y, Tagawa K, Fujino H, Unuma T. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis. Diabetes Res Clin Pract 1995;30:237-241.","DOI":"10.1016\/0168-8227(95)01188-9"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2009.08.009"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Fujioka T, Honda M, Yoshizaki T, Ogawa M, Matsuno H, Shimokawa K, Koyama K. A case of type 1 diabetes onset and recurrence of Graves’ disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C. Intern Med 2010;49:1987-1990.","DOI":"10.2169\/internalmedicine.49.3831"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Kawazoe T, Araki M, Lin Y, Ogawa M, Okamoto T, Yamamura T, Wakakura M, Murata M. New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C. Intern Med 2012;51:2625-2629.","DOI":"10.2169\/internalmedicine.51.7771"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000;23:1516-1526.","DOI":"10.2337\/diacare.23.10.1516"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0213-8"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Uonaga T, Yoshida K, Harada T, Shimodahira M, Nakamura Y. Case of type 1 diabetes mellitus following interferon β-1a treatment for multiple sclerosis. Intern Med 2012;51:1875-1877.","DOI":"10.2169\/internalmedicine.51.7609"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Zimmet PZ, Rowley MJ, Mackay IR, Knowles WJ, Chen QY, Chapman LH, Serjeantson SW. The ethnic distribution of antibodies to glutamic acid decarboxylase: presence and levels of insulin-dependent diabetes mellitus in Europid and Asian subjects. J Diabetes Complications 1993;7:1-7.","DOI":"10.1016\/1056-8727(93)90016-R"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1696"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, de Lalla F. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000;23:1177-1181.","DOI":"10.2337\/diacare.23.8.1177"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-558.","DOI":"10.1046\/j.1365-2036.2003.01681.x"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Fabbri C, Jaboli MF, Giovanelli S, Azzaroli F, Pezzoli A, Accogli E, Liva S, Nigro G, Miracolo A, Festi D. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol 2003;9:1487-1490.","DOI":"10.3748\/wjg.v9.i7.1487"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Sylvestre DL, Disston AR, Bui DP. Vogt-Koyanagi-Harada disease associated with interferon alpha-2b\/ribavirin combination therapy. J Viral Hepat 2003;10:467-470.","DOI":"10.1046\/j.1365-2893.2003.00456.x"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10319"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e318285257f"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2013.25.4.479"},{"key":"ref43","unstructured":"Mohokum M, Hartmann P, Schlattmann P. Association of Raynaud’s syndrome with interferons. A meta-analysis. Int Angiol 2012;31:408-413."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Huang X, Yuang J, Goddard A, Foulis A, James RF, Lernmark A, Pujol-Borrell R, Rabinovitch A, Somoza N, Stewart TA. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 1995;44:658-664.","DOI":"10.2337\/diab.44.6.658"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987;2:1423-1427.","DOI":"10.1016\/S0140-6736(87)91128-7"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1086\/315516"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2004.01.008"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Foulis AK, Farquharson MA, Hardman R. Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987;30:333-343.","DOI":"10.1007\/BF00299027"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993;260:1942-1946.","DOI":"10.1126\/science.8100367"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.","DOI":"10.7326\/0003-4819-139-10-200311180-00009"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26644"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Wiese M, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. J Hepatol 2005;43:590-598.","DOI":"10.1016\/j.jhep.2005.04.007"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001;34:730-739.","DOI":"10.1016\/S0168-8278(00)00097-0"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451-455.","DOI":"10.1136\/gut.2003.021691"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.07.043"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306227"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"ref58","unstructured":"Melmed S, Kenneth S, Polonsky KS, Larsen PR, Henry M. Kronenberg HM. Williams textbook of endocrinology. Type 1 Diabetes. 12th ed Philadelphia: Elsevier Inc; 2011;1436-1459."}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i1\/233.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T11:29:37Z","timestamp":1566214177000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i1\/233.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v21.i1.233","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}